SciSparc is set to start a Phase 2a study evaluating the safety and efficacy of SCI-110, its investigational cannabinoid-based therapy for Alzheimer’s disease and agitation. “We are very excited to begin our trial,” Adi Zuloff-Shani, PhD, chief technologies officer of SciSparc, said in a press release, noting that current off-label therapies for Alzheimer’s agitation have failed to provide relief for patients. “We believe that this trial will corroborate our belief that SCI-110 may constitute a…
You must be logged in to read/download the full post.
The post New Study Will Test Cannabinoid-based Therapy for Agitation appeared first on BioNewsFeeds.